Complement function in mAb-mediated cancer immunotherapy

This publication has 44 references indexed in Scilit:

• Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
  Journal of Clinical Oncology, 2003
• The mechanisms of action of rituximab in the elimination of tumor cells
  Seminars in Oncology, 2003
• Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activities
  Immunology, 2000
• Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack
  Journal of Biological Chemistry, 2000
• A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage
  Laboratory Investigation, 2000
• Regulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/αMβ2 - lntegrin Glycoprotein
  Critical Reviews in Immunology, 2000
• Expression and regulation by interferon-γ of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours
  European Journal Of Cancer, 1999
• Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells
  Gastroenterology, 1996
• Distribution of C3-Step Regulatory Proteins of the Complement System, CD35 (CRl), CD46 (MCP), and CD55 (DAF), in Hematological Malignancies
  Leukemia & Lymphoma, 1994
• Complement killing of human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)'2-cobra venom factor conjugate are equally cytotoxic
  Molecular Immunology, 1990